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Open access under CC BYDHEA and progesterone have a protective effect
on ribavirin-induced hemolysisTo the Editor:
We read with great interest the recent article by Scherzer et al.
who investigated the relationship between ITPA polymorphism
and decreased hemoglobin levels in 308 Austrian patients [1].
In their cohort, they conﬁrmed the protective effect of ITPA poly-
morphisms on ribavirin-induced anemia. However, surprisingly,
premenopausal females in their population were less likely
develop ribavirin-induced anemia irrespective of the protective
effect of ITPA mutations. In multivariate analysis of a >3 g/dl
decrease in hemoglobin, menopause was the most signiﬁcant
variable (OR = 2.814, 95% CI 1.027–7.714, p = 0.044). A similar
result was not observed when comparing men less than 50 and
older than 50. Scherzer et al. tried to advance explanations for
these differences between premenopausal and postmenopausal
women related to the protective effect of female hormones.
We have recently developed a new in vitro tool for analysis of
ribavirin-induced red blood cell lysis based on the ribavirin concen-
tration [2]. This test can be used to study molecules able to inhibit
ribavirin-induced hemolysis. We therefore used this test to evalu-
ate molecules associated with a physiological decrease in plasma
concentrations between premenopausal and postmenopausal
women. We tested the following molecules in the presence of
2 mM ribavirin: b-estradiol, estradiol, estrone, progesterone,
androstenedione, and DHEA. Under our experimental conditions,
in the presence of 2 mM ribavirin (intraerythrocytic ribavirin con-
centration in treated patients [3]), a hemolysis rate of about 20%
was obtained. The percentage hemolysis for this condition was
set to 100%. Interestingly, progesterone and DHEA strongly and
dose-dependently attenuated ribavirin-induced hemolysis
(Fig. 1). The various experimental conditions were repeated 6
times. For example, by adding DHEA at concentrations of
0.01 mg/ml and 0.02 mg/ml to the ribavirin medium, hemolysisJournal of Hepatology 201
-NC-ND license.was decreased by 31.87% (±2.9%, p <0.001) and 63.93% (±0.96%,
p <0.001), respectively. Addition of progesterone at a concentration
of 100 lM decreased hemolysis by 39.17% (±2.75%, p <0.001). On
the basis of our preliminary results, we also tested structural ana-
logs of progesterone (mifepristone, levonorgestrel, and predni-
sone), which also demonstrated protection towards ribavirin-
induced hemolysis but to a lesser extent (data not shown).
Plasma DHEA levels decrease progressively with age in both
men and women with a marked disparity of concentrations
observed in the same age-group [4]. Plasma DHEA levels are in
the range 600 to 3400 ng/ml in women between the ages of 25
and 44 years, and in the range 120 to 2500 ng/ml in women
between the ages of 45 and 75 years. The results presented in
Fig. 1 show that a small variation in the DHEA concentration
(from 0.01 mg/ml to 0.02 mg/ml) leads to a signiﬁcant reduction
of ribavirin-induced hemolysis. Circulating progesterone levels
fall to below 1 ng/ml in postmenopausal women.
These results may provide an explanation for the data
obtained by Scherzer et al. [1]. However, the way in which
these molecules counteract the adverse effects of ribavirin on
red blood cells remain unknown. It is commonly accepted that
ribavirin-induced hemolysis is the result of a marked decrease
in ATP levels in red blood cells, increasing susceptibility to
oxidation [5]. However, only limited evidence is available
concerning how ribavirin disrupts ATP homeostasis in red
blood cells. Several hypotheses can be proposed, such as con-
sumption of ATP for ribavirin phosphorylation of derivatized
triphosphate. Another explanation could be enzyme inhibition
of the salvage pathway of purine nucleotide synthesis in red
blood cells. The protective effect of DHEA and progesterone
on ribavirin-induced hemolysis could possibly be involved in
the regulation of red blood cell ATP metabolism. The addition4 vol. 60 j 894–901 897
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Fig. 1. Decreased ribavirin-induced hemolysis by adding progesterone and
DHEA. Percentage hemolysis in the presence of 2 mM ribavirin was set at 100%.
⁄ ⁄⁄
Letters to the Editorof protease inhibitors, boceprevir or telaprevir, to peginterfer-
on + ribavirin increases the frequency as well as the severity
of anemia [6]. According to our results, DHEA and/or
progesterone supplementation could be tested in patients trea-
ted for chronic hepatitis C, especially in the elderly to achieve
serum concentrations similar to those of women in their 20s
[7].
Finally, it could be interesting to quantify plasma DHEA and
progesterone levels in patients treated for chronic hepatitis C.
The concomitant decrease of these two hormones could corrobo-
rate the data reported by Scherzer et al. concerning the difference
in sensitivity to ribavirin-induced hemolysis in postmenopausal
women and women of reproductive age.
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prompted to further explore this issue. We investigated the
changes in parameters of erythropoiesis (hemoglobin, erythro-
poietin, reticulocyte count), iron status (ferritin, hepcidin), and
sexual hormones (estrogen, progesterone, FSH, LH) in each 10
healthy women (age: 31.2 ± 6.2) with or without hormonal con-
traception (ethinyl estradiol + various gestagens) during one
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